When combined together, the two reference drugs showed a synergic/additive effect on cell viability inhibition, comparable to that elicited by our newly synthesized compounds 1 and 7, confirming that the simultaneous TSPO/p53 activation could be useful in blocking tumor cell proliferation (Figure 8C,D). The gene discussed is TP53; the disease is neoplasm.